Coherus BioSciences
Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer.
Overview
Coherus BioSciences, based in Redwood City, California, built its business on biosimilars of pegfilgrastim and other biologics before refocusing on oncology. It licensed the anti-PD-1 antibody toripalimab from Junshi Biosciences for the United States and Canada and won FDA approval in October 2023 for recurrent or metastatic nasopharyngeal carcinoma with chemotherapy, the first drug approved in the United States for that disease. The company is developing toripalimab combinations and other immuno-oncology candidates. Company facts are from the official website and FDA approval records.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +5
- registry trials +30
Similar pages
not linked directly; found by shared links- CompanyAP Biosciences
Shares Oesophageal cancer, Head and neck squamous cell carcinoma.
- TrialJUPITER-06
Shares Toripalimab, Oesophageal cancer.
- TrialJUPITER-02
- PersonLi Zhang
- CompanyNeonc Technologies
Shares Oesophageal cancer, Head and neck squamous cell carcinoma.
- TreatmentHMBD-001
Shares Oesophageal cancer, Head and neck squamous cell carcinoma.
- PersonKen Kato
Shares Oesophageal cancer, Head and neck squamous cell carcinoma.
- TermFeeding tube (gastrostomy, PEG, jejunostomy)
Shares Oesophageal cancer, Head and neck squamous cell carcinoma.